Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Increased nonsterol isoprenoids, dolichol and ubiquinone, in the Smith-Lemli-Opitz syndrome: effects of dietary cholesterol.

Pappu AS, Connor WE, Merkens LS, Jordan JM, Penfield JA, Illingworth DR, Steiner RD.

J Lipid Res. 2006 Dec;47(12):2789-98. Epub 2006 Sep 18.

2.

Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia.

Donovan JM, Von Bergmann K, Setchell KD, Isaacsohn J, Pappu AS, Illingworth DR, Olson T, Burke SK.

Dig Dis Sci. 2005 Jul;50(7):1232-8.

PMID:
16047465
3.

Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys.

Mishra RG, Hermsmeyer RK, Miyagawa K, Sarrel P, Uchida B, Stanczyk FZ, Burry KA, Illingworth DR, Nordt FJ.

J Clin Endocrinol Metab. 2005 Jun;90(6):3706-14. Epub 2005 Mar 15.

4.

Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone.

Hermsmeyer RK, Mishra RG, Pavcnik D, Uchida B, Axthelm MK, Stanczyk FZ, Burry KA, Illingworth DR, Juan C, Nordt FJ.

Arterioscler Thromb Vasc Biol. 2004 May;24(5):955-61. Epub 2004 Mar 18.

5.
6.
7.

Feedback inhibition of the cholesterol biosynthetic pathway in patients with Smith-Lemli-Opitz syndrome as demonstrated by urinary mevalonate excretion.

Pappu AS, Steiner RD, Connor SL, Flavell DP, Lin DS, Hatcher L, Illingworth DR, Connor WE.

J Lipid Res. 2002 Oct;43(10):1661-9.

9.

Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus.

Ginsberg HN, Illingworth DR.

Am J Cardiol. 2001 Sep 20;88(6A):9H-15H. Review.

PMID:
11576520
10.

A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.

Illingworth DR, Crouse JR 3rd, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB; Simvastatin Atorvastatin HDL Study Group.

Curr Med Res Opin. 2001;17(1):43-50.

PMID:
11464446
11.

HMG-CoA reductase inhibitors.

Illingworth DR, Tobert JA.

Adv Protein Chem. 2001;56:77-114. Review. No abstract available.

PMID:
11329860
12.

Effect of a very-high-fiber vegetable, fruit, and nut diet on serum lipids and colonic function.

Jenkins DJ, Kendall CW, Popovich DG, Vidgen E, Mehling CC, Vuksan V, Ransom TP, Rao AV, Rosenberg-Zand R, Tariq N, Corey P, Jones PJ, Raeini M, Story JA, Furumoto EJ, Illingworth DR, Pappu AS, Connelly PW.

Metabolism. 2001 Apr;50(4):494-503.

PMID:
11288049
13.

Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia.

Ohashi K, Ishibashi S, Osuga J, Tozawa R, Harada K, Yahagi N, Shionoiri F, Iizuka Y, Tamura Y, Nagai R, Illingworth DR, Gotoda T, Yamada N.

J Lipid Res. 2000 Aug;41(8):1199-204.

14.

Lipid-lowering drug therapy: more knowledge leads to more problems for composers of guidelines.

Durrington PN, Illingworth DR.

Curr Opin Lipidol. 2000 Aug;11(4):345-9. No abstract available.

PMID:
10945714
15.

Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia.

Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, Kotze MJ, Heinonen TM, Black DM.

Atherosclerosis. 2000 Jun;150(2):421-8.

PMID:
10856535
16.

Management of hypercholesterolemia.

Illingworth DR.

Med Clin North Am. 2000 Jan;84(1):23-42. Review.

PMID:
10685126
17.

Angiotensin-converting enzyme and cardiovascular disease risk.

O'Malley JP, Maslen CL, Illingworth DR.

Curr Opin Lipidol. 1999 Oct;10(5):407-15. Review.

PMID:
10554703
18.

Dyslipidemia and atherosclerosis: how much more evidence do we need?

Illingworth DR, Durrington PN.

Curr Opin Lipidol. 1999 Oct;10(5):383-6. Review. No abstract available.

PMID:
10554699
19.

New risk factors for coronary heart disease.

Illingworth DR.

Am J Med. 1999 Aug 23;107(2A):19S-21S. Review. No abstract available.

PMID:
10484233
20.

Dual hepatic metabolism of cerivastatin--clarifications.

Guyton JR, Dujovne CA, Illingworth DR.

Am J Cardiol. 1999 Aug 15;84(4):497. No abstract available.

PMID:
10468102
21.

Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.

Stein EA, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, Davidson M, Graham K, Arensman F, Knopp RH, DuJovne C, Williams CL, Isaacsohn JL, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ.

JAMA. 1999 Jan 13;281(2):137-44.

PMID:
9917116
22.

Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia.

O'Malley JP, Maslen CL, Illingworth DR.

Circulation. 1998 May 12;97(18):1780-3.

PMID:
9603531
23.

Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group.

Gordon BR, Kelsey SF, Dau PC, Gotto AM Jr, Graham K, Illingworth DR, Isaacsohn J, Jones PH, Leitman SF, Saal SD, Stein EA, Stern TN, Troendle A, Zwiener RJ.

Am J Cardiol. 1998 Feb 15;81(4):407-11.

PMID:
9485128
24.

Rhabdomyolysis after taking atorvastatin with gemfibrozil.

Duell PB, Connor WE, Illingworth DR.

Am J Cardiol. 1998 Feb 1;81(3):368-9.

PMID:
9468088
25.

Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia.

Raal FJ, Pilcher GJ, Illingworth DR, Pappu AS, Stein EA, Laskarzewski P, Mitchel YB, Melino MR.

Atherosclerosis. 1997 Dec;135(2):249-56.

PMID:
9430375
26.

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.

Davidson MH, Stein EA, Dujovne CA, Hunninghake DB, Weiss SR, Knopp RH, Illingworth DR, Mitchel YB, Melino MR, Zupkis RV, Dobrinska MR, Amin RD, Tobert JA.

Am J Cardiol. 1997 Jan 1;79(1):38-42.

PMID:
9024733
27.

The apolipoprotein B Q3405E polymorphism has no effect on its low-density-lipoprotein receptor binding affinity.

Pullinger CR, Love JA, Liu W, Hennessy LK, Ghassemzadeh M, Newcomb KC, Illingworth DR, Kane JP.

Hum Genet. 1996 Dec;98(6):678-80.

PMID:
8931699
28.

Effect of Pravastatin in the Treatment of Patients with Type III Hyperlipoproteinemia.

Knopp RH, Illingworth DR, Stein EA, Ginsberg HN, Broyles FE, Behounek BD.

Am J Ther. 1996 Nov;3(11):755-762.

PMID:
11862234
29.

Dietary cholesterol feeding suppresses human cholesterol synthesis measured by deuterium incorporation and urinary mevalonic acid levels.

Jones PJ, Pappu AS, Hatcher L, Li ZC, Illingworth DR, Connor WE.

Arterioscler Thromb Vasc Biol. 1996 Oct;16(10):1222-8.

PMID:
8857917
30.

Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial.

Stein EA, Davidson MH, Dujovne CA, Hunninghake DB, Goldberg RB, Illingworth DR, Knopp RH, Miller VT, Frost P, Isaacsohn JL, Mitchel YB, Melino MR, Shapiro D, Tobert JA.

J Cardiovasc Pharmacol Ther. 1996 Apr;1(2):107-116.

PMID:
10684407
31.

A Randomized Multicenter Trial Comparing and Efficacy of Simvastatin and Fluvastatin.

Illingworth DR, Stein EA, Knopp RH, Hunninghake DB, Davidson MH, Dujovne CA, Miller VT, Tobert JA, Laskarzewski PM, Isaacsohn JL, Bacon SP, Tate AC.

J Cardiovasc Pharmacol Ther. 1996 Jan;1(1):23-30.

PMID:
10684396
32.

Role of dietary cholesterol in the optimal diet for the treatment of hypercholesterolemia.

Illingworth DR, Hatcher LF, Pappu AS, Newcomb KC, Connor WE.

Can J Cardiol. 1995 Oct;11 Suppl G:115G-117G.

PMID:
7585284
33.

Economics of lipid lowering with HMG CoA reductase inhibitors.

Illingworth DR.

Clin Cardiol. 1995 Jun;18(6):295, 363. No abstract available.

34.

Occurrence of a mutation associated with Wolman disease in a family with cholesteryl ester storage disease.

Maslen CL, Babcock D, Illingworth DR.

J Inherit Metab Dis. 1995;18(5):620-3.

PMID:
8598644
35.

Adverse ocular effects associated with niacin therapy.

Fraunfelder FW, Fraunfelder FT, Illingworth DR.

Br J Ophthalmol. 1995 Jan;79(1):54-6.

36.

Indications for low-density lipoprotein apheresis.

Gordon BR, Stein E, Jones P, Illingworth DR.

Am J Cardiol. 1994 Dec 1;74(11):1109-12.

PMID:
7977068
37.

Diurnal variations in the plasma concentrations of mevalonic acid in patients with abetalipoproteinaemia.

Pappu AS, Illingworth DR.

Eur J Clin Invest. 1994 Oct;24(10):698-702.

PMID:
7851471
38.

Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.

Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, Tun P, Zupkis RV, Greguski RA.

Arch Intern Med. 1994 Jul 25;154(14):1586-95.

PMID:
8031206
39.

Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.

Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ.

Lancet. 1994 Jun 18;343(8912):1554-5. No abstract available.

PMID:
7911877
40.

A review of clinical trials comparing HMG-CoA reductase inhibitors.

Illingworth DR, Tobert JA.

Clin Ther. 1994 May-Jun;16(3):366-85; discussion 365. Review.

PMID:
7923304
41.

Impact of increasing calcium in the diet on nutrient consumption, plasma lipids, and lipoproteins in humans.

Karanja N, Morris CD, Rufolo P, Snyder G, Illingworth DR, McCarron DA.

Am J Clin Nutr. 1994 Apr;59(4):900-7.

PMID:
8147337
42.

Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia.

Larsen ML, Illingworth DR, O'Malley JP.

Atherosclerosis. 1994 Apr;106(2):235-40.

PMID:
8060383
43.

Drug treatment of dyslipoproteinemia.

Larsen ML, Illingworth DR.

Med Clin North Am. 1994 Jan;78(1):225-45. Review.

PMID:
8283933
44.

Therapeutic use of lovastatin in the treatment of hypercholesterolemia.

Illingworth DR.

Clin Ther. 1994 Jan-Feb;16(1):2-26; discussion 1. Review.

PMID:
8205598
45.

Hyperlipidemia.

Duell PB, Illingworth DR.

Curr Ther Endocrinol Metab. 1994;5:475-84. No abstract available.

PMID:
7704776
46.

The effects of n-3 fatty acids on plasma lipids and lipoproteins and other cardiovascular risk factors in patients with hyperlipidemia.

Schmidt EB, Kristensen SD, De Caterina R, Illingworth DR.

Atherosclerosis. 1993 Nov;103(2):107-21. Review.

PMID:
8292089
47.

How effective is drug therapy in heterozygous familial hypercholesterolemia?

Illingworth DR.

Am J Cardiol. 1993 Sep 30;72(10):54D-58D. Review.

PMID:
8213497
48.

Lipoprotein metabolism.

Illingworth DR.

Am J Kidney Dis. 1993 Jul;22(1):90-7. Review.

PMID:
8322800
49.

Combination therapy with HMG CoA reductase inhibitors and gemfibrozil: practical or perilous?

Duell PB, Illingworth DR.

Heart Dis Stroke. 1993 May-Jun;2(3):260-2. No abstract available.

PMID:
8137035
50.

The influence of dietary n-3 fatty acids on plasma lipids and lipoproteins.

Illingworth DR, Schmidt EB.

Ann N Y Acad Sci. 1993 Mar 15;676:60-9. Review.

PMID:
8489156

Supplemental Content

Loading ...
Support Center